MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jacc.2024.04.011

Медицинская библиотека · Journal of the American College of Cardiology · 2024

Prognostic Value of a 6-Minute Walk Test in Patients With Transthyretin Cardiac Amyloidosis.

Ioannou Adam, Fumagalli Carlo, Razvi Yousuf, Porcari Aldostefano, Rauf Muhammad U, Martinez-Naharro Ana, Venneri Lucia, Moody William, Steeds Richard P, Petrie Aviva, Whelan Carol, Wechalekar Ashutosh, Lachmann Helen, Hawkins Philip N, Solomon Scott D, Gillmore Julian D, Fontana Marianna

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

The 6-minute walk test (6MWT) represents a comprehensive functional assessment that is commonly used in patients with heart failure; however, data are lacking in patients with transthyretin cardiac amyloidosis (ATTR-CA).

OBJECTIVES

This study aimed to assess the prognostic importance of the 6MWT in patients with ATTR-CA.

METHODS

A retrospective analysis of patients diagnosed with ATTR-CA at the National Amyloidosis Centre who underwent a baseline 6MWT between 2011 and 2023 identified 2,141 patients, of whom 1,118 had follow-up at 1 year.

RESULTS

The median baseline 6MWT distance was 347 m (Q1-Q3: 250-428 m) and analysis by quartiles demonstrated an increased death rate with each distance reduction (deaths per 100 person-years: 6.3 vs 9.2 vs 13.6 vs 19.0; log-rank P < 0.001). A 6MWT distance of <350 m was associated with a 2.2-fold higher risk of mortality (HR: 2.15; 95% CI: 1.85-2.50; P < 0.001), with a similar increased risk across National Amyloidosis Centre disease stages (P for interaction = 0.761) and genotypes (P for interaction = 0.172). An absolute (reduction of >35 m) and relative worsening (reduction of >5%) of 6MWT at 1 year was associated with an increased risk of mortality (HR: 1.80; 95% CI: 1.51-2.15; P < 0.001 and HR: 1.89; 95% CI: 1.59-2.24; P < 0.001, respectively), which was similar across the aforementioned subgroups. When combined with established measures of disease progression (N-terminal pro-B-type natriuretic peptide progression and outpatient diuretic intensification), each incremental increase in progression markers was associated with an increased death rate (deaths per 100 person-years: 7.6 vs 13.9 vs 22.4 vs 32.9; log-rank P < 0.001).

CONCLUSIONS

The baseline 6MWT distance can refine risk stratification beyond traditional prognosticators. A worsening 6MWT distance can stratify disease progression and, when combined with established markers, identifies patients at the highest risk of mortality.

Для цитирования: Ioannou Adam, Fumagalli Carlo, Razvi Yousuf, Porcari Aldostefano, Rauf Muhammad U, Martinez-Naharro Ana, Venneri Lucia, Moody William, Steeds Richard P, Petrie Aviva, Whelan Carol, Wechalekar Ashutosh, Lachmann Helen, Hawkins Philip N, Solomon Scott D, Gillmore Julian D, Fontana Marianna. Prognostic Value of a 6-Minute Walk Test in Patients With Transthyretin Cardiac Amyloidosis.. Journal of the American College of Cardiology. 2024. DOI: 10.1016/j.jacc.2024.04.011.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.